Switch-maintenance gemcitabine after first-line chemotherapy in patients with malignant mesothelioma (NVALT19): an investigator-initiated, randomised, open-label, phase 2 trial
Title:
Switch-maintenance gemcitabine after first-line chemotherapy in patients with malignant mesothelioma (NVALT19): an investigator-initiated, randomised, open-label, phase 2 trial
Author:
de Gooijer, Cornedine J van der Noort, Vincent Stigt, Jos A Baas, Paul Biesma, Bonne Cornelissen, Robin van Walree, Nico van Heemst, Robbert C Soud, Magdolen Youssef-El Groen, Harry J M den Brekel, Agnes J Staal-van Buikhuisen, Wieneke A Bootsma, Gerben P Dammeijer, Floris van Tinteren, Harm Lalezari, Ferry Aerts, Joachim G Burgers, Jacobus A